Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of Telcyta in combination with Caelyx versus Caelyx as second-line therapy in platinum refractory or resistant ovarian cancer
2006-000366-36Phase 3Completed
- Sponsor
- Telik, Inc.
- Start
- Feb 2006
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of canfosfamide in ovarian cancer (2 arms), sponsored by Telik, Inc. Primary endpoints: Objective response rate and Progression-free survival. Started Feb 2006; status: completed.
02
Drugs
canfosfamide
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2006-000366-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000366-36.